Journal of Infection Prevention, published by SAGE Publications Ltd, is a pivotal resource in the fields of nursing, public health, and infectious diseases. With an ISSN of 1757-1774 and an E-ISSN of 1757-1782, this journal primarily serves as a platform for disseminating innovative research and comprehensive reviews aimed at enhancing infection control practices and health policy formulation. As of 2023, it holds a prestigious position within category quartiles, ranking Q2 in Advanced and Specialized Nursing and Q3 in Health Policy, Infectious Diseases, as well as Public Health, Environmental and Occupational Health, underscoring its relevance and influence in these arenas. Researchers, practitioners, and students are encouraged to explore the journal's content to contribute to the advancement of infection prevention strategies and the overall improvement of healthcare systems. With a convergence timeline from 2009 to 2024, the Journal of Infection Prevention is committed to publishing high-quality articles that address current challenges in infection control, thus playing a crucial role in the ongoing dialogue among health professionals.

Current Infectious Disease Reports, published by SPRINGER, is a leading journal dedicated to advancing knowledge in the field of infectious diseases. With an ISSN of 1523-3847 and an E-ISSN of 1534-3146, this peer-reviewed journal has established itself as a vital resource for researchers and healthcare professionals since its inception in 1999. The journal's impact in the academic community is underscored by its Q1 ranking in Infectious Diseases for 2023, placing it in the top quartile of influential journals in the field. Furthermore, it holds a respectable position at rank #95 out of 344 in the Scopus database, reflecting its substantial contribution to medicine and public health. While currently not an open access journal, it offers a wealth of articles covering the latest research, case studies, and reviews, making it an indispensable tool for those aiming to stay at the forefront of infectious disease science. As we navigate an era marked by emerging and re-emerging infectious threats, Current Infectious Disease Reports remains committed to providing high-quality, relevant research that supports evidence-based practice and informs future studies globally.

Antibiotics-Basel is a prestigious multidisciplinary journal published by MDPI, dedicated to advancing the field of antibiotic research and management. Since its inception in 2012 as an Open Access publication, the journal has established itself as a vital resource for researchers and professionals, offering an accessible platform for the dissemination of innovative findings in Biochemistry, Infectious Diseases, Microbiology, and Pharmacology. With a solid impact in its category, Antibiotics-Basel holds a Q1 ranking in critical areas such as Pharmacology and Pharmacology, Toxicology and Pharmaceutics, making it an influential journal in its field. The journal publishes high-quality research articles, reviews, and communications that are essential for advancing our understanding of antibiotic mechanisms, resistance, and therapeutic applications. Researchers are invited to submit their manuscript to contribute to this growing body of knowledge and collaborate in the fight against antibiotic resistance and infectious diseases.

Journal of Hospital Infection, published by W B SAUNDERS CO LTD, stands as a pivotal resource in the infectious diseases, medicine, and microbiology sectors. With an impressive impact factor positioning it in the Q1 quartile across its relevant categories, this journal not only ranks highly—#32 out of 344 in Infectious Diseases and #17 out of 140 in Medical Microbiology—but also exemplifies a commitment to advancing knowledge and practice in hospital infection control. Since its inception in 1980, the journal has become a vital platform for disseminating research that informs clinical practices, promotes safety in health care environments, and enhances medical education. While access is non-open, the journal's extensive scope and rigorously peer-reviewed contributions ensure its relevance and significance to researchers, professionals, and students aiming to stay at the forefront of this dynamic field. The journal’s headquarters in London underscores its international relevance, making it an essential reference for anyone involved in combating hospital-acquired infections.

Annals of Clinical Microbiology and Antimicrobials, published by BMC, is a leading open-access journal that has been fostering scientific discourse in the fields of microbiology and infectious diseases since its inception in 2002. With an established reputation for excellence, this journal is positioned in the prestigious Q1 category across multiple disciplines, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology as of 2023. This journal serves as a vital platform for researchers, healthcare professionals, and students, promoting the latest advancements in clinical microbiology and antimicrobial research. Access to its invaluable content is open to all, reflecting the commitment to disseminate knowledge universally. The Annals of Clinical Microbiology and Antimicrobials is based in the United Kingdom and continues to pave the way for innovation and discussions that shape the future of clinical practices in microbiology.

Antimicrobial Resistance and Infection Control is a leading open access journal published by BMC, dedicated to the dissemination of research in the critical area of antimicrobial resistance and its impact on infection control practices. Since its inception in 2012, the journal has quickly established itself as a vital resource for researchers, healthcare professionals, and policymakers, featuring a robust array of studies that address the escalating threats posed by antimicrobial resistance across various contexts. With its impressive Q1 rankings across multiple categories—including Infectious Diseases, Microbiology, Pharmacology, and Public Health—the journal’s influence is underscored by its consistent placement in the upper echelons of academic research. Furthermore, it holds commendable ranks in Scopus, with percentiles placing it in the top tier of its respective fields. The journal serves as an essential platform for innovative research and discussions aimed at curbing the threats of antimicrobial resistance, thereby supporting the global health community in striving for effective solutions to safeguard public health.

BMC Infectious Diseases is a premier open-access journal published by BMC in the United Kingdom, dedicated to the field of infectious diseases. Established in 2001, this journal has been at the forefront of disseminating high-quality, peer-reviewed research, contributing significantly to the global understanding of infectious pathogens and their impact on public health. With a 2023 Scopus ranking of #100 out of 344 in the Medicine - Infectious Diseases category, and a notable Q1 quartile classification, it stands as a vital resource for researchers and professionals alike. Authors benefit from the journal's broad reach and visibility, ensuring their work is accessible to a wide audience. Access options are fully open, allowing for seamless dissemination of knowledge in the ongoing battle against infectious diseases. With an established history of publishing groundbreaking studies, BMC Infectious Diseases plays a crucial role in addressing critical issues and advancing research in the ever-evolving landscape of infectious diseases.

Infectious Diseases Now is a premier academic journal dedicated to the evolving field of infectious diseases, published by Elsevier France - Éditions Scientifiques Médicales Elsevier. With an ISSN of 2666-9927 and an E-ISSN of 2666-9919, this journal stands at the forefront of disseminating critical research and clinical insights from 2021 to 2024. The journal's commitment to open access means that groundbreaking studies are readily available to researchers, healthcare professionals, and students, fostering a collaborative approach to tackling global health challenges. As evidenced by its Q2 quartile ranking in the 2023 Scopus category of Infectious Diseases, and its impressive position within the top 25% of its field, Infectious Diseases Now serves as an essential resource for those involved in the study and management of infectious diseases. By publishing high-quality research, case studies, and reviews, the journal plays a pivotal role in advancing knowledge and improving patient care in this vital area of medicine.

Welcome to the Journal of Microbiology Immunology and Infection, a premier academic publication established in 1998 and now proudly owned by Elsevier Taiwan. As an Open Access journal since 2016, it provides unrestricted access to groundbreaking research in the fields of immunology, microbiology, and infectious diseases, making it an essential resource for researchers, practitioners, and students alike. The journal holds impressive rankings, including Q1 status in categories such as Infectious Diseases and Microbiology (medical), and a notable 92nd percentile in its Scopus ranking for Medicine - Infectious Diseases. With a dedicated focus on advancing knowledge and fostering collaboration within the scientific community, the Journal of Microbiology Immunology and Infection is committed to publishing high-impact research that significantly influences practice and policy in healthcare and life sciences. The journal is also recognized for its contribution to the ongoing dialogue surrounding contemporary issues in immunology and infection, positioning it as a vital platform for scholarly exchange and innovation.

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.